Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in Taiwan

SIMPLE SUMMARY: The comparative effectiveness and safety of the standard dose and lower doses of pembrolizumab in non-small-cell lung cancer (NSCLC) patients still remains limited. We conducted a retrospective multi-institutional cohort study of patients newly initiating pembrolizumab in Taiwan. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Kai-Cheng, Shao, Shih-Chieh, Chen, Hui-Yu, Chan, Yuk-Ying, Fang, Yueh-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909459/
https://www.ncbi.nlm.nih.gov/pubmed/35267465
http://dx.doi.org/10.3390/cancers14051157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909459/
https://www.ncbi.nlm.nih.gov/pubmed/35267465
http://dx.doi.org/10.3390/cancers14051157

Ejemplares similares